A PYMNTS Company

US: Justice Department may seek damages from generic drugmakers for price-fixing

By  |  January 21, 2018

According to Bloomberg, some generic drug firms are under pressure in response to a speech delivered by US Department of Justice (DOJ) antitrust division chief Makan Delrahim at George Mason University’s law school. During the speech he said the DOJ may sue generic drug companies to recover damages over alleged pricey-fixing, adding that if taxpayers were overcharged due to collusion to raise prices, then seeking remedies may be appropriate.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    If taxpayers were overcharged because drugmakers conspired to raise the price of drugs, the Justice Department will consider suing to seek damages, Makan Delrahim, the division’s chief, said in remarks Friday 19, at George Mason University’s law school in Virginia.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    “To the extent that taxpayers have had to pay that bill, I think the taxpayers should recover,” he said. “We will get involved on the civil side and recover damages for the US government.”

    Mylan, Teva’s, and Endo are among more than a dozen companies targeted by the Justice Department and state attorneys general in a multi-year investigation into generic drug pricey-fixing. So far, the probe has led to guilty pleas from two former executives of Heritage Pharmaceuticals, a subsidiary of Emcure.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.